Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale
Executive Summary
Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.
You may also be interested in...
AstraZeneca Joins The $35 Club With Cap On Inhaler Copays
The British drug maker’s move follows that of Boehringer Ingelheim earlier this month, which itself followed increasing political scrutiny on out-of-pocket costs.
AstraZeneca Joins The $35 Inhaler Club; Medicare Patients Waiting On Congress For Membership
AZ’s move follows Boehringer’s announcement earlier this month and parallels what insulin sponsors did – but almost in reverse. For inhalers, political pressure on out-of-pocket costs has produced copay caps in the commercial market first, not Medicare.
Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients
Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.